Respira Therapeutics
Manufacturing · New Mexico, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
5901 Indian School Rd NE 107, Albuquerqu...Phone Number
(505) 200-9557Website
www.respiratherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Respira Therapeutics
Respira Therapeutics is focused on developing innovative inhalation products for cardiopulmonary diseases, particularly targeting pulmonary arterial hypertension (PAH). Their advanced particle engineering and proprietary device technologies aim to enhance drug delivery to the lung periphery, providing acute relief from symptoms like breathlessness and fatigue. The company is currently conducting Phase 2 clinical trials for their lead product candidate, RT234-PAH, which is designed for as-needed use by patients. With a commitment to pioneering respiratory therapies, Respira seeks to deliver substantial therapeutic benefits to patients worldwide.Explore more
Respira Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Respira Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Respira Therapeutics launches new products
Check if Respira Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Respira Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Respira Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Respira Therapeutics
Funding: Get notified immidiatlly once Respira Therapeutics has new funding data
Check out if Respira Therapeutics is spiking on competitors!
Click to see if Respira Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Respira Therapeutics
Compare insights from companies similar to Respira Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Respira Therapeutics
<$5M
1-10
Private
<$5M
2010
RK
Raj KewalramaniSenior VP, Product Development Manufacturing (Drug & Device)
Company Profile Activity
Activity Insights
Respira Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Respira Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Respira Therapeutics.
Respira Therapeutics financials insights
Gather financial insights about Respira Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$2.3M
Debt
$150K
Respira Therapeutics Tech Stack
A closer look at the technologies used by Respira Therapeutics
See more technologies
Respira Therapeutics News & Media
Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference
PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Respira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary arterial hypertension (PAH) patients can utilize on an as-needed (pro re nata or PRN) basis to acutely increase exercise tolerance and reduce exertional symptoms, today announced that the Company will present results from its recently-completed RT234 Phase 2b CPET trial in PAH patiRespira Therapeutics Announces First Patient Dosed in Phase 2b VIPAH-PRN 2b Trial of RT234 in Patients with Pulmonary Arterial Hypertension (PAH)
PALO ALTO, Calif., April 5, 2022 /PRNewswire/ -- Respira Therapeutics, Inc. a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung, announced today that the first...Respira to Present Clinical Data on RT234-PAH Patient-Controlled Treatment to Acutely Improve Episodic Symptoms in Pulmonary Arterial Hypertension (PAH) Patients
ALBUQUERQUE, N.M., Oct. 16, 2020 /PRNewswire/ -- Respira Therapeutics, Inc., a clinical-stage company developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung, announced today clinical data...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Respira Therapeutics
Sign Up For FreeTo access detailed company insights
Respira Therapeutics is focused on developing innovative inhalation products for cardiopulmonary diseases, particularly targeting pulmonary arterial hypertension (PAH). Their advanced particle engineering and proprietary device technologies aim to enhance drug delivery to the lung periphery, providing acute relief from symptoms like breathlessness... Read More
